Fact CheckerSign in

NCT06572800Completed

Tka Assay for CDK4/6i

Use of DiviTum-TKa as a Biomarker Assay for CDK4/6 Inhibitor Medication Compliance and Drug-Drug Interaction Assessment in ER/PR Positive Metastatic Breast Cancer

Source: ClinicalTrials.gov · Last updated 8 Oct 2025

Brief summary (registry, in English)

This clinical trial assesses whether using a test developed by DiviTum can identify optimal levels of CDK 4/6 inhibitor medications in the blood and whether assessing medical compliance and drug-drug interactions can optimize (improve) these levels in patients with estrogen receptor (ER) or progesterone receptor (PR) positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and are receiving CDK 4/6 inhibitors. CDK4/6 inhibitors in combination with endocrine therapy (ET) is first line treatment for metastatic hormone positive (ER/PR positive) breast cancer (mBC). Thymidine kinase is a biomarker (biological molecule found in blood, other body fluids, or tissues that is a sign of a condition or disease) that reflects cell proliferation (an increase in the number of cells as a result of cell growth and cell division). DiviTum-thymidine kinase activity (TKa) is a Food and Drug Administration approved assay which showed that a TKa is associated with the decreased likelihood of disease progression within 30 days or 60 days post testing. Using the DiviTum-TKa may improve medication compliance and remove potential drug-drug interactions in patients with ER/PR positive HER2-negative MBC.

Status (registry)
Completed
Study type
Interventional
Enrollment
34 (actual)
First submitted
22 Aug 2024
Start date
5 Sept 2023
Primary completion date
16 Sept 2025
Lead sponsor
Yale University
NCT number
NCT06572800

What you commit to

  • Study type: Interventional
  • Participants enrolled: 34
  • From 5 Sept 2023 to the primary completion date, 16 Sept 2025
  • 18 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participants without evidence of metastatic disease prior to registration.
  • Participants with prior use of CDK4/6 inhibitor therapy.

Other

  • Participants who are unable to provide informed consent for the trial.

Who the study is looking for

  • Participants must have histologically confirmed metastatic ER-positive (\> 10%), PR-positive or PR-negative, and HER2-negative (0 by immunohistochemistry \[IHC\] or if +1 or +2 by IHC, not amplified by fluorescence in situ hybridization \[FISH\]) breast cancer; ER positivity, PR positivity, and HER2 negativity as per the 2018 joint American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  • Participants must be starting CDK4/6 inhibitor and endocrine therapy as part of first-line therapy per standard of care and be previously CDK4/6 inhibitor-naïve.
  • Participants must be enrolled prior to starting CDK4/6 inhibitor therapy.
  • Participants must be ≥ 18 years of age.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status \< 3.
  • Willing and able to provide written informed consent for the trial.

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (18)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Smilow Cancer Hospital-Derby Care Center
Coordinator of this site? Confirm its status
DerbyUnited StatesUnknown status
Smilow Cancer Hospital Care Center-Fairfield
Coordinator of this site? Confirm its status
FairfieldUnited StatesUnknown status
Smilow Cancer Hospital Care Center at Glastonbury
Coordinator of this site? Confirm its status
GlastonburyUnited StatesUnknown status
Smilow Cancer Hospital Care Center at Greenwich
Coordinator of this site? Confirm its status
GreenwichUnited StatesUnknown status
Smilow Cancer Hospital Care Center - Guilford
Coordinator of this site? Confirm its status
GuilfordUnited StatesUnknown status
Smilow Cancer Hospital-Hamden Care Center
Coordinator of this site? Confirm its status
HamdenUnited StatesUnknown status
Smilow Cancer Hospital Care Center at Saint Francis
Coordinator of this site? Confirm its status
HartfordUnited StatesUnknown status
Yale-New Haven Hospital Saint Raphael Campus
Coordinator of this site? Confirm its status
New HavenUnited StatesUnknown status
Yale University
Coordinator of this site? Confirm its status
New HavenUnited StatesUnknown status
Smilow Cancer Center/Yale-New Haven Hospital
Coordinator of this site? Confirm its status
New HavenUnited StatesUnknown status
Yale-New Haven Hospital North Haven Medical Center
Coordinator of this site? Confirm its status
North HavenUnited StatesUnknown status
Smilow Cancer Hospital-Orange Care Center
Coordinator of this site? Confirm its status
OrangeUnited StatesUnknown status
Smilow Cancer Hospital Care Center at Long Ridge
Coordinator of this site? Confirm its status
StamfordUnited StatesUnknown status
Smilow Cancer Hospital-Torrington Care Center
Coordinator of this site? Confirm its status
TorringtonUnited StatesUnknown status
Smilow Cancer Hospital Care Center-Trumbull
Coordinator of this site? Confirm its status
TrumbullUnited StatesUnknown status
Smilow Cancer Hospital-Waterbury Care Center
Coordinator of this site? Confirm its status
WaterburyUnited StatesUnknown status
Smilow Cancer Hospital Care Center - Waterford
Coordinator of this site? Confirm its status
WaterfordUnited StatesUnknown status
Smilow Cancer Hospital Care Center - Westerly
Coordinator of this site? Confirm its status
WesterlyUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.